135
Views
12
CrossRef citations to date
0
Altmetric
Drug Profile

Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes

&
Pages 9-14 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

M. Evans, M. Wolden, J. Gundgaard, B. Chubb & T. Christensen. (2015) Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Journal of Medical Economics 18:1, pages 56-68.
Read now
Fei Wang, Justine Surh & Manmeet Kaur. (2012) Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes, Metabolic Syndrome and Obesity 5, pages 191-204.
Read now

Articles from other publishers (10)

Sejal Mistry, Ksenia N. Tonyushkina, Valeria C. Benavides, Abha Choudhary, Lina Huerta‐Saenz, Neha S. Patel, Farid H. Mahmud, Ingrid Libman & Mark A. Sperling. (2022) A centennial review of discoveries and advances in diabetes: Children and youth. Pediatric Diabetes 23:7, pages 926-943.
Crossref
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek & Dilek Gogas Yavuz. (2021) Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Frontiers in Endocrinology 12.
Crossref
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen & Barrie Chubb. (2018) Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia. Diabetes Therapy 9:3, pages 1201-1216.
Crossref
Lori Berard & Gail MacNeill. (2015) Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus. Canadian Journal of Diabetes 39:1, pages 4-9.
Crossref
Cheow Peng Ooi, Tzer Hwu Ting & Seng Cheong Loke. (2014) Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
M. Evans, M. Wolden, J. Gundgaard, B. Chubb & T. Christensen. (2014) Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Diabetes, Obesity and Metabolism 16:4, pages 366-375.
Crossref
Francisco Javier Ampudia-Blasco. (2014) Aspectos clínicamente relevantes para pacientes diabéticos en tratamiento con insulina: prevención de hipoglucemias y flexibilidad en la administración. Avances en Diabetología 30:1, pages 1-8.
Crossref
R. G. Josse & V. Woo. (2013) Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin. Diabetes, Obesity and Metabolism 15:12, pages 1077-1084.
Crossref
Luigi F. Meneghini. (2012) Insulin therapy for type 2 diabetes. Endocrine 43:3, pages 529-534.
Crossref
Anastasia N. Mavrogiannaki & Ilias N. Migdalis. (2012) Long-acting basal insulin analogs: latest developments and clinical usefulness. Therapeutic Advances in Chronic Disease 3:6, pages 249-257.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.